THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. LENVATINIB OR SORAFENIB FOR TREATMENT OF NTRK FUSION-POSITIVE METASTATIC THYROID CANCER

被引：0
|
作者：
Carlson, J. [1 ]
Suh, K. [2 ]
Xia, F. [3 ]
Williamson, T. [3 ]
Sullivan, S. [4 ]
机构：
[1] Univ Washington, Seattle, WA USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Bayer US LLC, Whippany, NJ USA
[4] Univ Washington, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Seattle, WA 98195 USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN11
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. ENTRECTINIB FOR TREATMENT OF METASTATIC FUSION-POSITIVE CANCERS IN CHILDREN AND YOUNG ADULTS
    Suh, K.
    Kang, A.
    Singh, R.
    Williamson, T.
    Sullivan, S.
    VALUE IN HEALTH, 2024, 27 (06) : S44 - S45
  • [2] THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB VS. IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF METASTATIC NTRKGENE FUSION-POSITIVE CANCERS
    Suh, K.
    Kang, A.
    Ko, G.
    Williamson, T.
    Liao, N.
    Sullivan, S.
    VALUE IN HEALTH, 2023, 26 (06) : S55 - S55
  • [3] The Potential Long-Term Comparative Effectiveness of Larotrectinib vs. Entrectinib for Second-Line Treatment of NTRK Fusion-Positive Metastatic Non-Small Cell Lung Cancer
    Roth, Joshua A.
    Carlson, Josh J.
    Williamson, Todd
    Sullivan, Sean D.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [4] The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
    Roth, Joshua A.
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (08): : 981 - 986
  • [5] A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER"
    Ogale, Sarika
    Zerbini, Clarissa Emy Higuchi
    Antoniou, Miranta
    Freund, Romain
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12): : 1616 - 1617
  • [6] A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER" RESPOND
    Roth, Joshua A.
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12): : 1617 - 1618
  • [7] The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer
    Suh, Kangho
    Carlson, Josh John
    Xia, Fang
    Williamson, Todd E.
    Sullivan, Sean D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] The patential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma
    Suh, Kangho
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (06): : 622 - 630
  • [9] The potential long-term comparative effectiveness of larotrectinib versus regorafenib or trifluridine/tipiracil for treatment of metastatic TRK fusion colorectal cancer
    Suh, Kangho
    Carlson, Josh John
    Xia, Fang
    Williamson, Todd E.
    Sullivan, Sean D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [10] Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers
    Suh, Kangho
    Carlson, Josh J.
    Xia, Fang
    Williamson, Todd
    Sullivan, Sean D.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1011 - 1019
12345